
WE CLAIM:

1. A compound of Formula (VI):



(VI)

or a pharmaceutically acceptable salt thereof, wherein:

X is selected from -C(=O)-, -C(=O)-O-, -CR^5R^6-O-C(=O)-, -CR^5R^6-O-C(=O)-O-, and a bond;

Y is selected from -C(=O)-, -C(=O)-O-, -CR^5R^6-O-C(=O)-, -CR^5R^6-O-C(=O)-O-, -P(=O)(O-C_{6-12} aryl)-NH-CR^4C(=O)-O-, and a bond;

Z is selected from -C(=O)-, -C(=O)-O-, and a bond;

W is selected from -C(=O)-, -C(=O)-O-, and a bond;

R^1 is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12}cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy;

R^2 is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12}cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, $(CR^5R^6)_z$-C_{5-12} heteroaryl, and $(CR^5R^6)_z$-C_{1-6} alkyl ester, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, oxo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy;


R^3 is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12}cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, oxo, C_{1-6} alkyl, C_{3-12} cycloalkyl, or hydroxy, and wherein said aryl can be optionally substituted with one to three groups independently selected from halo, oxo, C_{1-6} alkyl, C_{3-12} cycloalkyl, hydroxy, and C_{1-6} alkyl ester;

R^4 is selected from the group consisting of hydrogen, C_{1-3} alkyl, and $(CH_2)_z$-cycloalkyl;

R^5 and **R^6** are each independently selected from hydrogen, a halogen, C_{1-3} alkyl, and C_{3-6} cycloalkyl; and

R^7 is selected from hydrogen, C_{1-21} alkyl and $(CR^5R^6)_z$-C_{5-12}cycloalkyl, wherein at least one of R^1, R^2 and R^3 is not hydrogen; and z is 0, 1, 2, 3, 4, 5, or 6.

2. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

X is selected from -C(=O)-, -C(=O)-O-, -CR^5R^6-O-C(=O)-, -CR^5R^6-O-C(=O)-O-, and a bond;

Y is selected from -C(=O)-, -C(=O)-O-, -CR^5R^6-O-C(=O)-, -CR^5R^6-O-C(=O)-O-, -P(=O)(O-C_{6-12} aryl)-NH-CR^4C(=O)-O-, and a bond;

Z is selected from -C(=O)- and a bond;

R^1 is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12} cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy;

R^2 is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12} cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy;


R^3 is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12} cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy;

R[4] is selected from the group consisting of hydrogen, C_{1-3} alkyl and $(CH_2)_z$-cycloalkyl;

R[5] and **R[6]** are each independently selected from hydrogen, a halogen, C_{1-3} alkyl, and C_{3-6} cycloalkyl; and

wherein at least one of R^1, R^2 and R^3 is not hydrogen; and z is 0, 1, 2, 3, 4, 5, or 6.


3. The compound as claimed in claim 1 or 2, wherein the compound is of Formula (II):



(II)

or a pharmaceutically acceptable salt thereof.


4. The compound as claimed in claim 1 or 2, wherein the compound is of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof.

5. The compound as claimed in claim 1 or 2, wherein the compound is of Formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof.

6. The compound as claimed in any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein

X is selected from -C(=O)-, -CR^5R^6-O-C(=O)-, and a bond;

Y is selected from -C(=O)-, -CR^5R^6-O-C(=O)-, and a bond;

Z is a bond, and $\mathbf{R^1}$ is hydrogen;

$\mathbf{R^2}$ is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12} cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy; and

$\mathbf{R^3}$ is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12} cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy,

wherein z is 0, 1, 2, 3, 4, 5, or 6.

7. The compound as claimed in any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein

X is selected from -C(=O)-O-, -CR^5R^6-O-C(=O)-O-, and a bond;

Y is selected from -C(=O)-O-, -CR^5R^6-O-C(=O)-O-, and a bond;


Z is a bond, and $\mathbf{R^1}$ is hydrogen;

$\mathbf{R^2}$ is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12} cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy; and

$\mathbf{R^3}$ is selected from the group consisting of hydrogen, C_{1-21} alkyl, $(CR^5R^6)_z$-C_{3-12} cycloalkyl, $(CR^5R^6)_z$-C_{5-12}heterocyclyl, $(CR^5R^6)_z$-C_{6-12} aryl, and $(CR^5R^6)_z$-C_{5-12} heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group can be optionally substituted with one to three groups independently selected from halo, C_{1-6} alkyl, C_{3-12} cycloalkyl and hydroxy,

wherein z is 0, 1, 2, 3, 4, 5, or 6.

8. The compound as claimed in claim 1 or 2, wherein the compound is of Formula (V):



(V)

or a pharmaceutically acceptable salt thereof.

9. The compound as claimed in any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein:

X is selected from -C(=O)-, -C(=O)-O-, and a bond;

Y is selected from -C(=O)-, -C(=O)-O-, and a bond;

Z is a bond, and **R^1** is hydrogen;

R^1 is selected from hydrogen and C_{1-14} alkyl;


R^2 is selected from C_{1-10} alkyl, $(CR^5R^6)_z$-C_{3-12}cycloalkyl, and $(CR^5R^6)_z$-C_6 aryl, wherein said aryl can be optionally substituted with a halo; and

R^3 is selected from C_{1-10} alkyl, $(CR^5R^6)_z$-C_{3-12}cycloalkyl, and $(CR^5R^6)_z$-C_6 aryl, wherein said aryl can be optionally substituted with a halo, and


wherein **R^5** and **R^6** are hydrogen,

wherein z is 0, 1, 2, 3, 4, 5, or 6.


10. The compound as claimed in any one of claims 1-9 having the structure:




,




,




,


















,







,




































,


,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,









,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,



,

,

,

,

,

,

.




,




,




,




,




,




,




,




,




,









,




,




,



,

,

,

,

,

,




,




,




,




,




,




,




,




,













,




,




,



,

,

,

,

,

,

,

,

,

,




,




,




,




,




,




,




,




,




,





,





,



NH2
N
Cl
N
N
O
O
O
HO
,



H2N
N
Cl
N
N
O
O
O
HO
,


H2N
N
Cl
N
N
O
O
O
O
HO
,



NH2
N
Cl
N
N
O
O
O
O
HO
,


NH2
N
Cl
N
N
O
O
O
HO
,



H2N
N
Cl
N
N
O
O
O
O
HO
,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




.




,




.




,









,




,




,












,




,




,




,




,




,




,




,




,




,




,







,




,




,




,




,




,




,




,





,





,



,



,


,



.


,



,




,




,




,




,




,




,







,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,









,






,



,

,
,

,

,

,


O
HN
O
N
HO
O
N
N
Cl
HO


,


O
O
O
N
O
N
HO
O
N
N
Cl
HO


,


O
HN
O
N
HO
O
N
N
Cl
HO


,


O
O
O
N
O
N
HO
O
N
N
Cl
HO


,



,

















,

















,

or a pharmaceutically acceptable salt thereof.

11. The compound as claimed in any one of claims 1-9 having the structure:


,

,

,

,

,

,

,

,

,

,

,

,

, or

, or a pharmaceutically acceptable salt thereof.

11. The compound as claimed in any one of claims 1-10 having the structure:


,

,

,

,

,

,

,

,

,

,

,

,

, or

, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound or salt as claimed in any one of claims 1-11, and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition as claimed in claim 12, wherein the composition is injectable, or adapted for injection.


14. A pharmaceutical composition as claimed in claim 12 or 13, further comprising one or more additional therapeutic agents selected from the group consisting of lenacapavir, raltegravir, lamivudine, abacavir, ritonavir, dolutegravir, darunavir, atazanavir, emtricitabine, tenofovir, elvitegravir, rilpivirine, lopinavir, doravirine and islatravir.

15. A combination comprising the compound or salt as claimed in any one of claims 1-10, or the pharmaceutical composition as claimed in any one of claims 12-14, and one or more additional therapeutic agents selected from capsid inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs).

16. The combination comprising the compound or salt as claimed in any one of claims 1-10, or the pharmaceutical composition as claimed in any one of claims 12-14, and one or more additional therapeutic agents selected from lenacapavir, raltegravir, lamivudine, abacavir, ritonavir, dolutegravir, darunavir, atazanavir, emtricitabine, tenofovir, elvitegravir, rilpivirine, lopinavir, and doravirine.

17. The combination as claimed in claim 16, wherein the additional therapeutic agent is lenacapavir.

Dated this 21st day of August 2025



Archana Shanker (IN/PA-149)
Of Anand and Anand Advocates
Agents for the Applicants